{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:31Z","timestamp":1740144091194,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40261-022-01200-3","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T03:29:16Z","timestamp":1663126156000},"page":"807-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant\/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-9432","authenticated-orcid":false,"given":"Elena","family":"Beyzarov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Caubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"1","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40264-020-01035-x","volume":"44","author":"E Beyzarov","year":"2021","unstructured":"Beyzarov E, Chen Y, Julg R, Naim K, Shah J, Gregory WW, Ayoub A, Caubel P. Global safety database summary of COVID-19-related drug utilization-safety surveillance: a sponsor\u2019s perspective. Drug Saf. 2021;44(1):95\u2013105. https:\/\/doi.org\/10.1007\/s40264-020-01035-x.","journal-title":"Drug Saf"},{"key":"1200_CR2","unstructured":"Centers for Disease Control and Prevention. CDC coronavirus disease 2019 (COVID-19): people with certain medical conditions. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html#:~:text=Like%20adults%2C%20children%20with%20obesity,very%20sick%20from%20COVID%2D19. Accessed 18 Jul 2022."},{"issue":"SI","key":"1200_CR3","doi-asserted-by":"publisher","first-page":"SI37","DOI":"10.1093\/rheumatology\/keab250","volume":"60","author":"EH Tan","year":"2021","unstructured":"Tan EH, Sena AG, Prats-Uribe A, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60(SI):SI37\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1200_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaad.2021.08.065","volume":"86","author":"V Pahalyants","year":"2022","unstructured":"Pahalyants V, Murphy WS, Klebanov N, et al. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022;86(1):252\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.065.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1200_CR5","doi-asserted-by":"publisher","first-page":"e4124","DOI":"10.1093\/cid\/ciaa1488","volume":"73","author":"KM Andersen","year":"2021","unstructured":"Andersen KM, Mehta HB, Palamuttam N, et al. Association between chronic use of immunosuppresive drugs and clinical outcomes from coronavirus disease 2019 (COVID-19) hospitalization: a retrospective cohort study in a large US health system. Clin Infect Dis. 2021;73(11):e4124\u201330.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1200_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/jim-2021-001853","volume":"69","author":"J Wang","year":"2021","unstructured":"Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: a rapid systematic review of case reports and case series. J Investig Med. 2021;69(6):1253\u20135.","journal-title":"J Investig Med"},{"issue":"10","key":"1200_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.884121","volume":"2","author":"ME Flacco","year":"2022","unstructured":"Flacco ME, Soldato G, Acuti Martellucci C, Di Martino G, Carota R, Caponetti A, Manzoli L. Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study. Front Public Health. 2022;2(10): 884121.","journal-title":"Front Public Health"},{"issue":"1","key":"1200_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jmv.27281","volume":"94","author":"S Sotoodeh Ghorbani","year":"2022","unstructured":"Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: a systematic review and meta-analysis. J Med Virol. 2022;94(1):44\u201353. https:\/\/doi.org\/10.1002\/jmv.27281.","journal-title":"J Med Virol"},{"issue":"5","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/23744235.2020.1871066","volume":"53","author":"SM Piri","year":"2021","unstructured":"Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis (Lond). 2021;53(5):315\u201324.","journal-title":"Infect Dis (Lond)."},{"key":"1200_CR10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/ajt.15936","volume":"20","author":"JJ Hsu","year":"2020","unstructured":"Hsu JJ, Gaynor P, Kamath M, Fan A, Al-Saffar F, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant. 2020;20:1911\u20135.","journal-title":"Am J Transplant"},{"key":"1200_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa093","volume":"26","author":"J Jacobs","year":"2020","unstructured":"Jacobs J, Clark-Snustad K, Lee S. Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib. Inflamm Bowel Dis. 2020;26: e64.","journal-title":"Inflamm Bowel Dis"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.semarthrit.2020.05.010","volume":"50","author":"S Sharmeen","year":"2020","unstructured":"Sharmeen S, Elghawy A, Zarlasht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum. 2020;50:680\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/ajt.15897","volume":"20","author":"L Ning","year":"2020","unstructured":"Ning L, Liu L, Li W, Liu H, Wang J, Yao Z, et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report. Am J Transplant. 2020;20:1864\u20138.","journal-title":"Am J Transplant"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"R Haberman","year":"2020","unstructured":"Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases: case series from New York. N Engl J Med. 2020;383:85\u20138.","journal-title":"N Engl J Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01200-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T18:19:55Z","timestamp":1664993995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01200-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01200-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"7 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Pfizer Inc and may hold stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The analyses for this study were conducted retrospectively using deidentified patient data; as such, this study was deemed exempt by the institutional review board and informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"No specific custom code was created for the study. We utilized an SAP Business Objects (Desktop Intelligence Version 12.6.2.1782) based application to analyze the study data. For more details, please contact the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors met the below criteria for authorship: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and, drafting the work or revising it critically for important intellectual content; and, final approval of the version to be published; and, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}